市場調查報告書

重組人Endostatin 的中國市場的投資分析

Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 907270
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
重組人Endostatin 的中國市場的投資分析 Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023
出版日期: 2019年08月20日內容資訊: 英文 30 Pages
簡介

本報告提供中國的重組人Endostatin 市場相關調查分析,肺癌症的發生率,市場情形,價格,開發趨勢等相關的系統性資訊。

第1章 重組人Endostatin 的基本概念

  • 適應
  • 開發
  • 專利、政府核准

第2章 中國的重組人Endostatin 的銷售額

  • 銷售量
  • 銷售量
  • 銷售額:各劑型

第3章 中國的重組人Endostatin 的主要製造商分析

  • 重組人Endostatin 的主要廠商的市場佔有率分析
  • Yantai Medgenn Co., Ltd.

第4章 中國的重組人Endostatin 的價格

  • Yantai Medgenn Co., Ltd. (Endostar)
  • 潛在的競爭企業分析

第5章 中國的重組人Endostatin 市場預測

  • 市場發展的影響因素
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 1908398

Description

In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society.

In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

Recombinant Human Endostatin, an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis.

The sales value of Recombinant Human Endostatin increased sharply after it was launched in China. It rose from CNY 148 million in 2013 to CNY 272 million in 2017, representing a CAGR of 16.47%.

By Aug. 2019, only one enterprise's Recombinant Human Endostatin has been approved to be sold in China. In the context of worsening environmental pollution and over 300 million smokers, the number of lung cancer patients in China will continue to increase in the next few years. Therefore, the market size of Recombinant Human Endostatin will keep expanding and more enterprises will launch their Recombinant Human Endostatin products in China.

Topics covered:

  • Incidence of lung cancer in China
  • Status of China's Recombinant Human Endostatin market
  • Prices of Recombinant Human Endostatin in China
  • Development trends of Recombinant Human Endostatin in China

Table of Contents

1 Relevant Concepts of Recombinant Human Endostatin

  • 1.1 Indications for Recombinant Human Endostatin
  • 1.2 Development of Recombinant Human Endostatin in China
  • 1.3 Patents and Government Approval on Recombinant Human Endostatin in China

2 Sales of Recombinant Human Endostatin in China, 2013-2017

  • 2.1 Sales Value
  • 2.2 Sales volume
  • 2.3 Sales of Recombinant Human Endostatin by Dosage Form in China, 2013-2017

3 Analysis on Major Manufacturers of Recombinant Human Endostatin in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Endostatin
  • 3.2 Yantai Medgenn Co., Ltd.

4 Prices of Recombinant Human Endostatin in China, 2017-2018

  • 4.1 Yantai Medgenn Co., Ltd. (Endostar)
  • 4.2 Analysis on Potential Competitors

5 Prospect of China's Recombinant Human Endostatin Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Recombinant Human Endostatin Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Sales of Recombinant Human Endostatin in China, 2013-2017
  • Chart Sales Value of Recombinant Human Endostatin in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Human Endostatin in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Endostatin in Parts of China, 2013-2017
  • Chart Sales Value of Recombinant Human Endostatin Injection in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Endostatin Injection in China, 2013-2017
  • Chart Sales Value of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd., 2013-2017
  • Chart Prices of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd. in Parts of China, 2017-2018
  • Chart Patents on Recombinant Human Endostatin in China
  • Chart Government Approval on Recombinant Human Endostatin in China
  • Chart Forecast on Sales Value of Recombinant Human Endostatin in China, 2019-2023
Back to Top